The Boston Globe (Boston, MA)

Organogenesis critic seen target of SEC probe

The Boston Globe (Boston, MA) | April 16, 1996 | Copyright

Evan Sturza, one of the most ardent critics of Organogenesis Inc. -- the Canton developer of laboratory-grown skin to treat patients with venous ulcers -- is reportedly under investigation for unusual short-selling trading last year. Sturza, the 34-year-old editor and publisher of the New York-based Sturza Medical Investment Letter, said the Securities and Exchange Commission and the US Attorney have asked for his 1995 trading records involving Organogenesis.

Last Friday, Business Week reported the SEC, the Chicago Board Options Exchange and the US Attorney's office in Brooklyn…

Read the rest of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Organogenesis critic seen target of SEC probe
Newspaper article from: The Boston Globe ...trading records involving Organogenesis. Last Friday, Business Week reported the SEC, the Chicago Board...drive down the price of Organogenesis. Short sellers borrow...reportedly complained about Organogenesis to the SEC, stating that advance...

For more facts and information, see all results

Find more facts and information related to the article Organogenesis critic seen target of SEC probe